hotspot -WSS

hotspot

author：fashion 2025-09-30 10:33:15 - browse：34116

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

Wikipedia

WSS

Change Healthcare can notify patients about the breach, HHS says

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Woman returns to dialysis after doctors remove transplanted pig kidney

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Eli Lilly expects to double planned employment in Boston center

HHS leader on health, climate change and biopharma emissions

focus

hotspot

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

STAT Summit: How a Chicago ER doctor tackles gun violence

Affirmative action in medical school literally saved lives

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

United colonoscopy coverage change 'may cost lives,' doctors say

How climate

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The EU Joint Clinical Assessment needs to live up to its promise

Medical records are filled with copy

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

Woman returns to dialysis after doctors remove transplanted pig kidney

Impact of Dobbs ruling felt at reproductive medicine meeting

Beam Therapeutics to lay off 20% of its staff, re

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

How to increase colonoscopy rates? Looks like an AI can help

Ultragenyx gene therapy for rare liver ailment succeeds in late

entertainment

Wikipedia

explore

focus